View All

All Publications for Public Policy and Health Care Sector Reform

Switching Pharmaceutical Products from Prescription to Over-the-Counter: The Debate in the US	Published Article 2012-12-01	By Dr. Richard Rozek
Economics as a Guide to Developing Public Policies for Biosimilar Pharmaceutical Products	Published Article 2012-11-01	By Dr. Richard Rozek
Economic Issues Raised in the FDA’s Proposed Rule on Removing the Essential-Use Designation for Albuterol MDIs	Report 2004-08-13	By Dr. Richard Rozek et al.
The Impact on Patients and Payers of Designating Albuterol a Non-Essential Use of an Ozone Depleting Substance	Regulatory Filing 2003-09-09	By Dr. Richard Rozek with former NERA Consultant Emily Bishko Radel
Broad-Based Compulsory Licensing of Pharmaceutical Technologies: Unsound Public Policy	Published Article 2001-07-01	By Dr. Richard Rozek et al.
Reimbursing Generics in the UK: Is There a Better Way?	Published Article 2001-03-01	By NERA Special Advisor Ian Senior
The Effects of Compulsory Licensing on Innovation and Access to Health Care	Published Article 2000-11-01	By Dr. Richard Rozek
Regulatory Influences on the Decision to Introduce Pharmaceutical Products in Japan	Published Article 1998-09-01	By Dr. Richard Rapp and Dr. Richard Rozek with Gakushuin University Professor of Economics Tshuruhiko Nambu
Risk-Adjustment and Its Implications for Efficiency and Equity in Health Care Systems	Report 1996-01-01	By Dr. Thomas McCarthy with Keith Davies, John Gaisford and Ullrich Hoffmeyer
Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation	Published Article 1992-09-01	By Dr. Richard Rapp and Dr. Richard Rozek
1

NERA Economic Consulting

All Publications for Public Policy and Health Care Sector Reform